Cancer Risk Assessment for Hereditary Cancer Risk
Trial Summary
What is the purpose of this trial?
This study aims to identify the optimal method to recognize, risk stratify, and provide follow-up care for individuals at risk of hereditary cancer. The study team will conduct a Hybrid Type II comparative effectiveness-implementation trial, with a mixed methods component and process/formative evaluations for stakeholder engagement. The study team will evaluate three methods for identifying and risk-stratifying individuals at risk of hereditary cancer and providing post-risk stratification longitudinal care.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment for chemotherapy-induced peripheral neuropathy?
The research indicates that while there are no preventive therapies with significant clinical efficacy for chemotherapy-induced peripheral neuropathy (CIPN), promising novel agents like histone deacetylase 6 (HDAC6) inhibitors are in early clinical trials. Additionally, drug repurposing, such as using metformin, may offer alternative therapeutic options.12345
Is the treatment for hereditary cancer risk assessment safe for humans?
The safety data for treatments related to chemotherapy-induced peripheral neuropathy (CIPN) suggest that while there are no preventive therapies with significant clinical efficacy, the only agent recommended for painful CIPN is duloxetine. This indicates that while some treatments are considered safe, their effectiveness varies.15678
How does usual care for CIPN differ from other treatments?
Usual care for chemotherapy-induced peripheral neuropathy (CIPN) involves standard medications and treatment adjustments like delaying or reducing chemotherapy doses, but there are no recommended preventive treatments for CIPN. Unlike novel agents being tested, such as HDAC6 inhibitors, usual care focuses on managing symptoms rather than preventing them.156910
Research Team
Douglas Corley, MD, PhD
Principal Investigator
Division of Research, Kaiser Permanente Northern California
Eligibility Criteria
This trial is for adults who've been members of Kaiser Permanente Northern California for at least 2 years, have visited a clinic in the past two years, and have an email on file. It's not open to those outside the targeted area, in the no-contact database, or unable to read English.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Risk Assessment
Participants undergo cancer risk assessment using various methods, including usual care, a short web-based questionnaire, or a detailed family history survey
Follow-up
Participants are monitored for outcomes and complete PRO surveys at 6 and 12 months post-assessment
Treatment Details
Interventions
- Online Cancer Risk Assessment
- Usual care
Usual care is already approved in United States, European Union for the following indications:
- Chemotherapy-induced peripheral neuropathy (CIPN)
- Chemotherapy-induced peripheral neuropathy (CIPN)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kaiser Permanente
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborator